scholarly journals Blueberry Consumption Improves Glycemic Control, Triglycerides and Liver Enzymes in US Veterans with Type 2 Diabetes (P06-124-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Kim Stote ◽  
Margaret Wilson ◽  
Deborah Hallenbeck ◽  
Krista Thomas ◽  
Joanne Rourke ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Hemoglobin A1c ◽  
Liver Enzymes ◽  
Cardiometabolic Health ◽  
Treatment Groups ◽  
Freeze Dried ◽  
Us Veterans ◽  
Study Participants

Abstract Objectives The study investigated the effects of blueberry consumption on biomarkers of glycemic control in US veterans with type 2 diabetes. Methods In a double-blind, placebo-controlled parallel study, fifty-five men (mean baseline characteristics: 67 years; weight, 103 kg; body mass index, 34 kg/m2) with type 2 diabetes were randomly assigned to 1 of 2 treatment groups for 8 weeks. The treatment groups were either 22 g of a freeze-dried whole blueberry powder (equivalent to 1 cup of fresh blueberries; containing 845 mg phenolics and 470 mg anthocyanins) or 22 g of a blueberry placebo treatment (matched in energy and carbohydrate content to the blueberry treatment). The study participants were asked to consume 11 g of freeze-dried (equivalent to ½ cup of fresh blueberries) blueberry powder or placebo, reconstituted with 240 ml water, with their morning and evening meals along with their typical diet. Fasting blood samples were collected at the beginning and at the end of the study. Results Fructosamine (275.5 ± 4.1 µmol/L vs. 292.4 ± 7.9 µmol/L, respectively; P = 0.04) and hemoglobin A1C (7.1 ± 0.1% vs. 7.5 ± 0.2%, respectively; P = 0.03) were significantly lower for study participants consuming blueberries for 8 weeks compared with the placebo. In addition, triglycerides (160.6 ± 13.1 mg/dl vs. 183.9 ± 10.7 mg/dl, respectively; P = 0.03), aspartate transaminase (AST) (23.2 ± 1.4 units/L vs. 30.5 ± 2.7 units/L, respectively; P = 0.02) and alanine transaminase (ALT) (35.6 ± 1.5 units/L vs. 48.3 ± 2.9 units/L, respectively; P = 0.0003), were significantly lower for those consuming blueberries compared with the placebo. Glucose, insulin, total cholesterol, LDL cholesterol, HDL cholesterol and body weight were not significantly different after 8 weeks of consumption of blueberries compared with the placebo. Conclusions Consumption of 22 g of freeze-dried blueberries daily for 8 weeks results in better glycemic control, such as lowering of fructosamine and hemoglobin A1C. These results along with lower triglyceride concentrations show improvement in the liver enzymes, AST and ALT, which may beneficially affect the cardiometabolic health status of men with type 2 diabetes. Funding Sources The U.S. Highbush Blueberry Council; the study is the result of work supported with resources and the use of facilities at the Stratton VA Medical Center, Albany, NY, USA.

Abstract 013: High Prevalence and Rapid Increase of Cardiovascular Disease Risk Factors in Youth with Type 2 Diabetes: The TODAY Study Group

Circulation ◽  
2013 ◽  
Vol 127 (suppl_12) ◽  
Author(s):  
Fida Bacha ◽  
Samuel S Gidding ◽  
Sonia Caprio ◽  
Ruth Weinstock ◽  
Jane Lynch ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Glycemic Control ◽  
Hemoglobin A1c ◽  
Male Gender ◽  
High Risk Population ◽  
Cvd Risk Factors ◽  
Cvd Risk

Background The natural history of type 2 diabetes (T2D) in youth appears to differ from that in adults in that almost half of T2D youth in the “Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)” study had a rapid decline in beta cell function. The rate of change in risk for cardiovascular disease (CVD) in youth with T2D is not known. We tested the hypothesis that CVD risk factors are highly prevalent and rapidly progress over time in youth with T2D using longitudinal assessments of hypertension (HT), microalbuminuria (MA) and dyslipidemia obtained during the TODAY clinical trial of adolescents with recent onset T2D. Methods A cohort of 699 adolescents, aged 10-17 years, <2 years duration of T2D, body mass index (BMI) ≥85th percentile, Hemoglobin A1c (A1c) ≤8% on metformin therapy were randomized to metformin alone, metformin plus rosiglitazone, or metformin plus an intensive lifestyle intervention and followed over an average of 3.9 years. (range 2-6.5 years). Primary outcome was loss of glycemic control. Quarterly BP and annual MA were monitored with initiation and titration of therapy (ACE inhibitor) to maintain BP <130/80 or <95th percentile for age, gender, and height and MA <30 mcg/mg. Statin drugs were begun for LDL cholesterol (LDLC) ≥130 mg/dL or triglycerides ≥300 mg/dL. Change in the prevalence of CVD risk factors was examined accounting for the effect of treatment group, time, glycemic control, gender, and race-ethnicity. Results In this cohort, 319 (45•6%) reached primary glycemic outcome. HTN was observed in 11•6% of subjects at baseline and 33•8% by end of study (average follow-up 3•9 years). MA was found in 6•3% at baseline and rose to 16•6% at study end. Participants with LDLC ≥130 mg/dL or statin use increased from 4.5% to 10.7%. Male gender and higher BMI significantly increased the risk for HTN. Higher levels of hemoglobin A1c correlated with the risk of developing MA and dyslipidemia. Conclusion The prevalence of CVD risk factors increased rapidly among adolescents with T2D regardless of diabetes treatment. The greatest risk for HTN was male gender and higher BMI. The risk for microalbuminuria and worsening of dyslipidemia was related to glycemic control. Measures to address CVD risk are needed early in the disease course in this high risk population.

Perception of Family Support is Correlated with Glycemic Control in Greeks with Diabetes Mellitus

2001 ◽  
Vol 88 (3) ◽  
pp. 929-930 ◽  
Author(s):  
Ioannis Ilias ◽  
Eftichios Hatzimichelakis ◽  
Athanassios Souvatzoglou ◽  
Tanya Anagnostopoulou ◽  
Athanassios Tselebis
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Family Support ◽  
Hemoglobin A1c ◽  
Anglo Saxon ◽  
The Family ◽  
Of Greece

We studied 98 native Greek patients with Type 2 diabetes mellitus. Their degree of glycemic control, evaluated with glycated hemoglobin A1c levels, was correlated with perceived family support, assessed with the Family Support Scale. The different social context of Greece—and its corresponding perception of family support—influence glycemic control in a way that is at variance from data of some studies of Anglo-Saxon families. In conclusion, family support should be taken into consideration in the management of native Greek patients with Type 2 diabetes mellitus.

scholarly journals The Effect of Crocin Supplementation on Glycemic Control, Insulin Resistance and Active AMPK Levels in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

2020 ◽  
Author(s):  
Vahideh Behrouz ◽  
Ali Dastkhosh ◽  
Mehdi Hedayati ◽  
Meghdad Sedaghat ◽  
Maryam Sharafkhah ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Insulin Sensitivity ◽  
Glycemic Control ◽  
Hemoglobin A1c ◽  
Active Form ◽  
Group Analysis

Abstract Background Crocin as a carotenoid exerts anti-oxidant, anti-inflammatory, anti-cancer, neuroprotective and cardioprotective effects. Besides, the increasing prevalence of diabetes mellitus and its allied complications, and also patients' desire to use natural products for treating their diseases, led to the design of this study to evaluate the efficacy of crocin on glycemic control, insulin resistance and active adenosine monophosphate-activated protein kinase (AMPK) levels in patients with type-2 diabetes (T2D). Methods In this clinical trial with a parallel-group design, 50 patients with T2D received either 15-mg crocin or placebo, twice daily, for 12 weeks. Anthropometric measurements, dietary intake, physical activity, blood pressure, glucose homeostasis parameters, active form of AMPK were assessed at the beginning and at the end of the study.Results Compared with the placebo group, crocin improved fasting glucose level (P=0.015), hemoglobin A1c (P=0.045), plasma insulin level (P=0.046), insulin resistance (P=0.001), and insulin sensitivity (P=0.001). Based on the within group analysis, crocin led to significant improvement in plasma levels of glucose, insulin, hemoglobin A1c, systolic blood pressure, insulin resistance and insulin sensitivity. The active form of AMPK did not change within and between groups after intervention. Conclusions The findings indicate that crocin supplementation can improve glycemic control and insulin resistance in patients with T2D. Further studies are needed to confirm these findings. Trial Registration This study has been registered at Clinicaltrial.gov with registration number NCT04163757.

scholarly journals Effect of Blueberry Consumption on Cardiometabolic Health Parameters in Men with Type 2 Diabetes: An 8-Week, Double-Blind, Randomized, Placebo-Controlled Trial

2020 ◽  
Vol 4 (4) ◽  
Author(s):  
Kim S Stote ◽  
Margaret M Wilson ◽  
Deborah Hallenbeck ◽  
Krista Thomas ◽  
Joanne M Rourke ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Serum Insulin ◽  
Controlled Trial ◽  
Strong Association ◽  
Hdl Cholesterol ◽  
Cardiometabolic Health ◽  
Double Blind ◽  
Freeze Dried ◽  
Health Parameters

ABSTRACT Background Blueberries are dietary sources of polyphenols, specifically anthocyanins. Anthocyanins have been identified as having a strong association with type 2 diabetes risk reduction; however, to date few human clinical trials have evaluated the potential beneficial health effects of blueberries in populations with type 2 diabetes. Objectives We investigated the effects of blueberry consumption for 8 wk on cardiometabolic parameters in men with type 2 diabetes. Methods In a double-blind, parallel-arm, randomized controlled trial, 52 men who are US veterans [mean baseline characteristics: age, 67 y (range: 51–75 y); weight, 102 kg (range: 80–130 kg); BMI (in kg/m2), 34 (range: 26–45)] were randomly assigned to 1 of 2 intervention groups. The interventions were either 22 g freeze-dried blueberries or 22 g placebo. The study participants were asked to consume 11 g freeze-dried blueberries or placebo with each of their morning and evening meals along with their typical diet. Results Mean ± SE hemoglobin A1c (7.1% ± 0.1% compared with 7.5% ± 0.2%; P = 0.03), fructosamine (275.5 ± 4.1 compared with 292.4 ± 7.9 µmol/L; P = 0.04), triglycerides (179.6 ± 10.1 compared with 199.6 ± 19.9 mg/dL; P = 0.03), aspartate transaminase (23.2 ± 1.4 compared with 30.5 ± 2.7 units/L; P = 0.02), and alanine transaminase (35.6 ± 1.5 compared with 48.3 ± 2.9 units/L; P = 0.0003) were significantly lower for those consuming blueberries for 8 wk than for those consuming the placebo. Fasting plasma glucose concentrations; serum insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, and C-reactive protein concentrations; blood pressure; and body weight were not significantly different after 8 wk consumption of blueberries compared with the placebo. Conclusions Consumption of 22 g freeze-dried blueberries for 8 wk may beneficially affect cardiometabolic health parameters in men with type 2 diabetes. This trial was registered at clinicaltrials.gov as NCT02972996.

The Accuracy of Hemoglobin A1c and Fructosamine Evaluated by Long-Term Continuous Glucose Monitoring in Patients with Type 2 Diabetes Undergoing Hemodialysis

2021 ◽  
pp. 1-9
Author(s):  
Tobias Bomholt ◽  
Marianne Rix ◽  
Thomas Almdal ◽  
Filip K. Knop ◽  
Susanne Rosthøj ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Continuous Glucose Monitoring ◽  
Plasma Glucose ◽  
Hemoglobin A1c ◽  
Glucose Monitoring ◽  
Control Group ◽  
Glucose Levels ◽  
Sensor Glucose

<b><i>Introduction:</i></b> The accuracy of hemoglobin A1c (HbA1c) as a glycemic marker in patients with type 2 diabetes (T2D) receiving hemodialysis (HD) remains unknown. To assess accuracy, we compared HbA1c and fructosamine levels with interstitial glucose measured by continuous glucose monitoring (CGM) in patients with T2D receiving HD. <b><i>Methods:</i></b> Thirty patients in the HD group and 36 patients in the control group (T2D and an estimated glomerular filtration rate &#x3e;60 mL/min/1.73 m<sup>2</sup>) completed the study period of 17 weeks. CGM (Ipro2<sup>®</sup>, Medtronic) was performed 5 times for periods of up to 7 days (with 4-week intervals) during a 16-week period. HbA1c (mmol/mol), the estimated mean plasma glucose from HbA1c (eMPGA1c [mmol/L]) and fructosamine (μmol/L) was measured at week 17 and compared with mean sensor glucose levels from CGM. <b><i>Findings:</i></b> In the HD group, mean sensor glucose was 1.4 mmol/L (95% confidence interval [CI]: 1.0–1.8) higher than the eMPGA1c, whereas the difference for controls was 0.1 mmol/L (95% CI: −0.1–[0.4]; <i>p</i> &#x3c; 0.001). Adjusted for mean sensor glucose, HbA1c was lower in the HD group (−7.3 mmol/mol, 95% CI: −10.0–[−4.7]) than in the control group (<i>p</i> &#x3c; 0.001), with no difference detected for fructosamine (<i>p</i> = 0.64). <b><i>Discussion:</i></b> HbA1c evaluated by CGM underestimates plasma glucose levels in patients receiving HD. The underestimation represents a clinical challenge in optimizing glycemic control in the HD population. Fructosamine is unaffected by the factors affecting HbA1c and appears to be more accurate for glycemic monitoring. CGM or fructosamine could thus complement HbA1c in obtaining more accurate glycemic control in this patient group.

Effect of psychotherapy for depression via home telehealth on glycemic control in adults with type 2 diabetes: Subgroup analysis of a randomized clinical trial

2017 ◽  
Vol 24 (9) ◽  
pp. 596-602 ◽  
Author(s):  
Leonard E Egede ◽  
Rebekah J Walker ◽  
Elizabeth H Payne ◽  
Rebecca G Knapp ◽  
Ronald Acierno ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Older Adults ◽  
Glycemic Control ◽  
Subgroup Analysis ◽  
Repeated Measures ◽  
Controlled Trial ◽  
Treatment Groups ◽  
Design And Methods ◽  
The Impact

Objective We evaluated the impact of telemedicine-delivered behaviour activation treatment (BAT) on glycemic control in a subgroup of older adults with diabetes who participated in a randomized controlled trial for depression. Research design and methods We randomized older adults with major depression to same-room or telemedicine BAT. Each group received eight weekly sessions. For the subgroup analysis, we identified individuals with type 2 diabetes and obtained hemoglobin A1c at baseline and 12 months’ follow-up. We used mixed-effects models (MEM) for repeated measures analysis to compare the longitudinal mean A1c. We estimated model-derived mean A1c values and considered an adjusted model to account for baseline health status. Results We included 90 individuals with type 2 diabetes of the original 241 in the subgroup analysis (43 in telemedicine and 47 in same room). Treatment groups were not significantly different at baseline for demographics, depression, anxiety or A1c levels (telemedicine 6.9 vs. same room 7.3, p = 0.19). Baseline mean A1c for the telemedicine group remained at 6.9 (55 mmol/mol) at 12 months, whereas baseline mean A1c for the same-room group increased to 7.7 (61 mmol/mol). Longitudinal trajectories of model-derived mean A1c indicated a significant main effect of treatment group on mean A1c value at study end (difference = −0.82, 95% CI −1.41, −0.24). Adjusted analyses gave comparable results. Conclusions Telemedicine-delivered BAT was superior to same room in achieving lower mean A1c values in participants with type 2 diabetes, suggesting BAT-delivered via telemedicine is a viable treatment option for adults with diabetes.

scholarly journals The Eradication of Helicobacter pylori does not Affect Glycemic Control in Japanese Subjects with Type 2 Diabetes

2013 ◽  
Vol 4 ◽  
pp. JCM.S10828 ◽  
Author(s):  
Yoshiharu Wada ◽  
Yoshiyuki Hamamoto ◽  
Yukiko Kawasaki ◽  
Sachiko Honjo ◽  
Kanta Fujimoto ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Helicobacter Pylori ◽  
Glycemic Control ◽  
Hemoglobin A1c ◽  
Glycosylated Hemoglobin ◽  
Eradication Therapy ◽  
Glycosylated Hemoglobin A1c ◽  
H Pylori ◽  
Japanese Subjects

Since infection with Helicobacter pylori has been suggested to play a pathogenic role in diabetes mellitus, we investigated whether eradication therapy for H. pylori might affect glycemic control in Japanese subjects with type 2 diabetes. A total of 72 subjects (55 males, 17 females; aged 63.7 years) with type 2 diabetes who received eradication therapy for H. pylori were included. The change of their blood glycosylated hemoglobin (A1C) levels 3 months before (-3 m) the H. pylori eradication, as well as 3 months (3 m) and 6 months (6 m) after were evaluated. Their A1C levels did not show any significant change after therapy {6.9 [0.1]% (-3 m) to 7.0 [0.1]% (3 m); P = 0.3, 7.0 [0.1] (6 m); P = 0.3}. Our findings suggest that the eradication therapy for H. pylori does not, at least profoundly, affect glycemic control in Japanese subjects with type 2 diabetes.

Factors Associated with Poor Hemoglobin A1c Control in Patients with Type 2 Diabetes

2019 ◽  
Vol 15 (2) ◽  
pp. 164-170 ◽  
Author(s):  
Salam Alqudah ◽  
Anan S. Jarab ◽  
Eman A. Alefishat ◽  
Fadia Mayyas ◽  
Maher Khdour ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Medication Adherence ◽  
Glycemic Control ◽  
Hemoglobin A1c ◽  
Diabetes Management ◽  
Blood Glucose Control ◽  
Clinical Pharmacy Service ◽  
Diabetes Clinic ◽  
Factors Associated

Background: The limited implementation of clinical pharmacy service programs and the lack of studies identifying barriers to achieve blood glucose control have all attributed to the increased proportion of type 2 diabetes patients who have poor glycemic control in Jordan. Objective: To explore factors associated with higher HbA1c in patients with type 2 diabetes in Jordan. Methods: Variables including socio-demographics, disease and treatment factors were collected from171 patients with type2 diabetes at an outpatient diabetes clinic in Amman. Validated questionnaires were used to assess medication adherence, self-care activities, diabetes knowledge and healthrelated quality of life in addition to data collected from medical records. After the single-predictor analysis, stepwise linear regression was performed to develop a model with variables that best predicted hemoglobin A1c. Results: Medication adherence was inversely associated with HbA1c values (β = -0.275; t = 2.666; P < 0.01), indicating better glycemic control. Receiving insulin therapy was also associated with less HbA1c values and better glycemic control (β = - 0.184; t = 2.080; P < 0.05). Patients who had one or more comorbid conditions (β = 0.215; t = 2.264; P < 0.05) and those with longer diabetes duration (β = 0.092; t = 1.339; P < 0.05) were found to have significantly higher HbA1c values. Conclusion: Emphasizing medication adherence, particularly for patients with longer duration of diabetes and those with multiple comorbid diseases should be strongly considered in future diabetes management programs implemented to improve glycemic control in patients with type 2 diabetes.

Sign in / Sign up

Export Citation Format

Share Document